Article ; Online: Lycopodium Mitigates Oxidative Stress and Inflammation in the Colonic Mucosa of Acetic Acid-Induced Colitis in Rats.
Molecules (Basel, Switzerland)
2022 Volume 27, Issue 9
Abstract: Inflammatory bowel diseases (IBDs) such as ulcerative colitis (UC) and Crohn's disease (CD) are diseases of the gastrointestinal system involving genetic and environmental factors attributed to oxidative stress and inflammation. Targeting oxidative ... ...
| Abstract | Inflammatory bowel diseases (IBDs) such as ulcerative colitis (UC) and Crohn's disease (CD) are diseases of the gastrointestinal system involving genetic and environmental factors attributed to oxidative stress and inflammation. Targeting oxidative stress and inflammation by novel dietary compounds of natural origin convincingly appears to be one of the important therapeutic strategies to keep the disease in remission. As there is no permanent cure for IBD except for chronic long-term treatment or surgery, it is therefore imperative to investigate plant-based agents that are receiving attention for their therapeutic benefits to overcome the debilitating clinical conditions of IBD. Lycopodium (LYCO), a plant of tropical and subtropical origin and known by numerous names such as ground pine, club moss, or devil's claw, has been popularly used for centuries in traditional medicine including Chinese and Indian medicines. In the present study, the effect of LYCO has been investigated in an acetic acid (AA)-induced colitis model in Wistar rats. LYCO was orally administered at the dose of 50 mg/kg/day either 3 days before or 30 min after the induction of IBD and continued for 7 days by intrarectal administration of AA. The changes in body weight and macroscopic and microscopic analysis of the colon of rats of different experimental groups were observed on days 0, 2, 4, and 7. The levels of myeloperoxidase (MPO), reduced glutathione (GSH), and malondialdehyde (MDA) were measured. AA caused a significant reduction in body weight and increased macroscopic and microscopic ulcer scores along with a significant decline in antioxidant enzymes, superoxide dismutase (SOD), and catalase and antioxidant substrate, glutathione (GSH). There was a concomitant increased formation of malondialdehyde (MDA), a marker of lipid peroxidation, and raised myeloperoxidase (MPO) activity, a marker of neutrophil activation. Treatment with LYCO significantly improved IBD-induced reduction in body weight, improved histology, inhibited MDA formation, and restored antioxidants along with reduced MPO activity. AA also caused the release of proinflammatory cytokines such as interleukin-1β (IL-1β) and interleukin-23 (IL-23). Furthermore, AA also increased the levels of calprotectin, a protein released by neutrophils under inflammatory conditions of the gastrointestinal tract. LYCO treatment significantly reduced the release of calprotectin and proinflammatory cytokines. The results demonstrate that LYCO treatment has the potential to improve disease activity by inhibiting oxidative stress, lipid peroxidation, and inflammation along with histological preservation of colonic tissues. |
|---|---|
| MeSH term(s) | Acetic Acid/metabolism ; Animals ; Anti-Inflammatory Agents/therapeutic use ; Antioxidants/metabolism ; Body Weight ; Colitis/chemically induced ; Colitis/drug therapy ; Colitis/metabolism ; Colitis, Ulcerative/chemically induced ; Colitis, Ulcerative/drug therapy ; Colitis, Ulcerative/metabolism ; Cytokines/metabolism ; Glutathione/metabolism ; Inflammation/metabolism ; Inflammatory Bowel Diseases/pathology ; Intestinal Mucosa/metabolism ; Leukocyte L1 Antigen Complex/metabolism ; Leukocyte L1 Antigen Complex/pharmacology ; Leukocyte L1 Antigen Complex/therapeutic use ; Lycopodium ; Malondialdehyde/metabolism ; Oxidative Stress ; Peroxidase/metabolism ; Rats ; Rats, Wistar |
| Chemical Substances | Anti-Inflammatory Agents ; Antioxidants ; Cytokines ; Leukocyte L1 Antigen Complex ; Malondialdehyde (4Y8F71G49Q) ; Peroxidase (EC 1.11.1.7) ; Glutathione (GAN16C9B8O) ; Acetic Acid (Q40Q9N063P) |
| Language | English |
| Publishing date | 2022-04-26 |
| Publishing country | Switzerland |
| Document type | Journal Article |
| ZDB-ID | 1413402-0 |
| ISSN | 1420-3049 ; 1431-5165 ; 1420-3049 |
| ISSN (online) | 1420-3049 |
| ISSN | 1431-5165 ; 1420-3049 |
| DOI | 10.3390/molecules27092774 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.MO 81: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.